25.88

4.40% -1.19

Zymeworks Inc. (ZYME)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

$27.07

Aprire:

$27.03

Volume 24 ore:

482.75K

Relative Volume:

0.73

Capitalizzazione di mercato:

$1.90B

Reddito:

$81.26M

Utile/perdita netta:

$-102.66M

Rapporto P/E:

-18.92

EPS:

-1.3678

Flusso di cassa netto:

$-77.62M

1 W Prestazione:

-1.63%

1M Prestazione:

+13.26%

6M Prestazione:

+11.70%

1 anno Prestazione:

+89.46%

Intervallo 1D:

$25.36

$27.13

Intervallo di 1 settimana:

$24.70

$27.41

Portata 52W:

$11.51

$29.75

Zymeworks Inc. Stock (ZYME) Company Profile

Nome

Zymeworks Inc.

Settore

Healthcare (1096)

Industria

Biotechnology (616)

Telefono

604-678-1388

Indirizzo

1385 West 8th Avenue, Suite 540, Vancouver, BC

Dipendente

170

Cinguettio

@ZymeworksInc

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

ZYME's Discussions on Twitter

Compare ZYME vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ZYME Zymeworks Inc.	25.88	1.90B	81.26M	-102.66M	-77.62M	-1.3678
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-12-12	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2025-12-03	Iniziato	Citizens JMP	Mkt Outperform
2025-10-24	Ripresa	Wells Fargo	Equal Weight
2025-10-14	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-10-10	Iniziato	B. Riley Securities	Buy
2025-05-20	Iniziato	TD Cowen	Buy
2024-12-16	Aggiornamento	JP Morgan	Neutral → Overweight
2024-11-07	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-11-01	Downgrade	Wells Fargo	Overweight → Equal Weight
2023-03-21	Ripresa	Wells Fargo	Overweight
2023-01-04	Reiterato	H.C. Wainwright	Neutral
2022-12-20	Aggiornamento	Jefferies	Hold → Buy
2022-11-01	Downgrade	H.C. Wainwright	Buy → Neutral
2022-10-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-10-04	Ripresa	Wells Fargo	Overweight
2022-05-05	Aggiornamento	Guggenheim	Neutral → Buy
2022-03-15	Iniziato	Evercore ISI	Outperform
2021-12-10	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2021-11-17	Ripresa	Guggenheim	Neutral
2021-10-07	Iniziato	Jefferies	Hold
2021-03-31	Iniziato	Credit Suisse	Outperform
2021-02-25	Downgrade	SVB Leerink	Outperform → Mkt Perform
2021-02-08	Ripresa	H.C. Wainwright	Buy
2021-01-25	Downgrade	Citigroup	Buy → Neutral
2020-09-29	Ripresa	JP Morgan	Neutral
2020-08-06	Iniziato	SVB Leerink	Outperform
2020-01-10	Iniziato	Wolfe Research	Outperform
2019-12-09	Iniziato	JP Morgan	Neutral
2019-11-25	Iniziato	H.C. Wainwright	Buy
2019-11-20	Iniziato	Guggenheim	Buy
2019-09-30	Aggiornamento	Raymond James	Outperform → Strong Buy
2019-08-30	Iniziato	Stifel	Buy
2019-07-18	Iniziato	Deutsche Bank	Buy
2018-05-11	Aggiornamento	Barclays	Underweight → Equal Weight
2018-03-19	Iniziato	Raymond James	Outperform

Mostra tutto

Zymeworks Inc. Borsa (ZYME) Ultime notizie

Jul 08, 2026

Theravance stock down 3% after Zymeworks announces buyout - MSN

Jul 08, 2026

Jul 07, 2026

Zymeworks ZW49 from ZYMEantibody drug conjugate targets solid tumors - ad-hoc-news.de

Jul 07, 2026

Zymeworks Inc outlines its biotech strategy as investors track clinical progress - ad-hoc-news.de

Jul 07, 2026

Zymeworks: A Deep Dive (NASDAQ:ZYME) - Seeking Alpha

Jul 07, 2026

Jul 06, 2026

Form 4 Zymeworks Inc For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026

Zymeworks (ZYME) COO acquires 939 ESPP shares at discounted $22.22 - Stock Titan

Jul 06, 2026

Price to book forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView

Jul 06, 2026

Jul 05, 2026

Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI

Jul 05, 2026

Zymeworks Q1 2026 presentation: zanidatamab nears FDA decision - Investing.com

Jul 05, 2026

Zymeworks (ZYME) Breaks Out: +2.29% Rally Tests Key Resistance Near $27.63Buffered ETF - dars.gov.et

Jul 05, 2026

Jul 03, 2026

Zymeworks Inc outlines its antibody-drug conjugate strategy as investors watch oncology partnerships - ad-hoc-news.de

Jul 03, 2026

Jul 01, 2026

Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha

Jul 01, 2026

Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run - Yahoo Finance

Jul 01, 2026

Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP

Jul 01, 2026

Enterprise value to revenue forward of Zymeworks Inc. – BOATS:ZYME - TradingView

Jul 01, 2026

The Zymeworks ZW25 bispecific antibodya flexible HER2 therapy option for oncology partners - ad-hoc-news.de

Jul 01, 2026

Jun 30, 2026

Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU

Jun 30, 2026

Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? - Insider Monkey

Jun 30, 2026

After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals

Jun 30, 2026